RYTARY
What it isExtended-release levodopa replacement paired with carbidopa’s peripheral AADC inhibition; Parkinson disease.
Why this oneIt combines immediate- and extended-release beads to smooth motor fluctuations and reduce "off" time in Parkinson disease; it is not interchangeable mg-for-mg with IR Sinemet.
What limits itDyskinesia, nausea, orthostasis, and hallucinations can limit use; conversion from other levodopa products requires retitration.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Parkinson's disease / parkinsonism (levodopa-naive) | Adults | 23.75 mg/95 mg TID x3 days | 36.25 mg/145 mg TID (day 4); up to 97.5 mg/390 mg TID | 612.5 mg/2,450 mg per day |
| Parkinson's disease (converting from IR carbidopa-levodopa) | Adults | Per conversion table (Table 1) | Individualized, 3-5 times daily | 612.5 mg/2,450 mg per day |
Renal Undefined
Hepatic Undefined
Dosing frequency may be increased from TID up to 5 times daily; not interchangeable 1:1 with other carbidopa-levodopa products
Pregnancy No adequate human data; animal studies show developmental toxicity including teratogenicity — may cause fetal harm
Lactation Levodopa detected in human milk; may inhibit lactation (decreases prolactin); consider benefits vs risk
NO BOXED WARNINGS
Principal riskDyskinesia and motor fluctuation with cumulative exposure

Open Carbidopa/ levodopa ER in the interactive console ↗

